Últimas noticias sobre NKGen Biotech (OTC:NKGN) Bolsa

NKGen Biotech

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

NKGen Biotech Inc

TD Securities analyst Cherilyn Radbourne maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Buy and lowers the price target from $68 to $64.

News

Price Target

Analyst Ratings

TD Securities Maintains Buy on Brookfield Asset Mgmt, Lowers Price Target to $64

TD Securities analyst Brian Morrison maintains Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) with a Buy and raises the price target from $56 to $60.

TD Securities Maintains Buy on Gildan Activewear, Raises Price Target to $60

An <a href="https://www.benzinga.com/general/social-media/25/04/44799581/no-expiration-date-on-metas-antitrust-case-says-former-ftc-chair-ahead-of-trial">antitrust trial against </a>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has put the company's segments, such as Instagram and WhatsApp, into the spotlight, as the company could be forced to divest these units.
A Benzinga reader poll shows a potential break-up could be a value unlock for Meta Platforms as they share which new unit they would want to own.
What Happened: An<a href="https://www.benzinga.com/25/04/44821791/meta-platforms-used-buy-or-bury-strategy-to-monopolize-social-media-ftc-says"> antitrust trial by</a> the Federal Trade Commission could cast a shadow over Meta Platforms, with its first-quarter financial results due Wednesday after the market close.
The trial accuses Meta of using a "buy or bury" strategy to acquire competing companies, such as Instagram and WhatsApp. The trial highlighted how Meta also considered buying Snap Inc. and has shut down some of the companies it previously acquired.
While a forced spinoff or breakup for Meta Platforms might sound like a bad thing, it could ultimately unlock shareholder value through a sum-of-parts valuation. This could allow each unit to trade at higher multiples and highlight individual growth.
Benzinga recently asked readers if they think Meta could be worth more under a spinoff or break-up plan from the FTC.
"Meta Platforms could be forced to sell or spinoff Instagram and WhatsApp. If the spinoffs/sales happen which do you think describes what happens next?" Benzinga asked.
<ul>
<li>Sum of parts greater than current $1.27 trillion market cap: 50%</li>
<li>Sum of parts less than current $1.27 trillion market cap: 28%</li>
<li>Meta, Instagram and WhatsApp worth $1.27 trillion together still: 22%</li>
</ul>
The survey found that half of Benzinga readers believe Meta stock could be worth more with a forced spinoff or breakup.
Benzinga readers were also asked which future Meta unit they would most want to own if a breakup were to happen.
"If Meta splits into three separate companies, which would you be most interested in owning?" Benzinga asked.
<ul>
<li>Instagram: 43%</li>
<li>Meta Platforms/Facebook: 35%</li>
<li>WhatsApp: 23%</li>
</ul>
The poll found that Instagram would be the most coveted asset if traded individually.
Read Also: <a href="https://www.benzinga.com/general/social-media/25/04/45083272/meta-platforms-q1-earnings-preview-analyst-expects-weak-guidance-will-company-continue-streak-of-revenue-beats">Meta Platforms Q1 Earnings Preview: Analyst Expects Weak Guidance, Will Company Continue Streak Of Revenue Beats?</a>
Why It's Important: Meta acquired Instagram for $1 billion in 2012, beating out a bid of $500 million previously offered by Twitter.
At the time of the acquisition, many experts questioned the premium valuation given Instagram's 30 million users and limited revenue.
Since the acquisition, Instagram has become one of the most important growth segments for Meta with around two billion users and hundreds of millions of daily active users.
A break-up could see Instagram get a premium valuation given its higher growth and more monetization opportunities compared to the legacy Facebook brand. Of course, the Meta Platforms/Facebook company, under a new model, could have more of the company's AI technology and platforms, which could also receive a premium valuation.
Meta has argued against the antitrust allegations, highlighting competition from TikTok and YouTube, which is owned by Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>). The trial remains active and will ultimately decide if Meta is forced to make any moves.
META Price Action: Meta stock trades tat $538.05 on Wednesday versus a 52-week trading range of $427.11 to $740.91. Meta stock is down 10.2% year-to-date in 2025 and up 25% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44832468/snapchat-rejection-resurfaces-as-mark-zuckerberg-defends-meta-in-ftc-trial-and-the-tech-mogul-still-thinks-he-cou">Mark Zuckerberg Defends Meta In FTC Trial Over $6 Billion Offer To Acquire Snapchat: &#8216;We Would Have Accelerated Their Growth&#8217;</a></li>
</ul>
The study was conducted by Benzinga from April 23, 2025 through April 28, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 100 adults.
Photo: Shutterstock

Exclusives

Tech

Trading Ideas

GOOG

GOOGL

EXCLUSIVE: If Meta Is Forced To Divest Instagram, WhatsApp, Or Facebook, 43% Pick This Standout

The U.S. can't repay its $36 trillion of debt.
Here's what will happen instead:
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="307" height="164" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30174818/image-1-2.jpeg" alt="" class="wp-image-12012" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30174818/image-1-2.jpeg 307w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30174818/image-1-2-300x160.jpeg 300w" sizes="(max-width: 307px) 100vw, 307px" /></figure>
There are only 3 possible outcomes to addressing the debt problem:
1 &#8211; Default
2 &#8211; Print the debt away
3 &#8211; Technological &amp; deflationary boom
Let's look at all 3 
1 &#8211; Default
If the U.S. decides not to pay back its debt, the consequences would be massive.
The entire system is built on trust…and defaulting would destroy all trust in the U.S.
The dollar would collapse, credit markets would freeze, and financial panic would ensue.
It would be a Great Depression 2.0-style event.
2 &#8211; Print
If the U.S. printed its debt away, we'd experience extreme inflation.
Possibly Weimar Republic or Zimbabwe levels of inflation.
Basic necessities would be unaffordable. Not fun.
3 &#8211; Technological &amp; deflationary boom
New technology could theoretically boost productivity to the point where the economy outgrows its debt.
Tech is deflationary because it increases productivity and reduces costs over time.
Many believe that AI, cryptocurrency, and humanoid robots are the deflating counterbalance we need to combat our debt.
So what exactly will happen?
Likely a combination of short to medium-term money printing.
Followed by a long-term solution of technological innovation.
The U.S. dollar likely won't spiral into irrelevancy like many believe.
The British pound was once the reserve currency. Today, it's still the 5th most economically relevant currency on earth.
The dollar could experience a similar fate…while tech digs us out of this hole we're in.
But no matter what happens, one thing is for certain:
The dollar is the measuring stick we use to value asset prices.
And as that measuring stick erodes, asset prices will nominally rise.
So buy assets, or get left behind.
&#x2A;&#x2A;
Hey there!
Welcome to the WOLF Financial Newsletter.
Join over 13,000 savvy investors building wealth and mastering advanced investing strategies live on Twitter Spaces. Subscribe below to be part of the action:
<a href="https://marketmadness-newsletter.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Subscribe</a>
WOLF Financial has driven liquidity, user growth, and brand awareness across TradFi and Crypto through marketing, advisory, and partnership services. See more&nbsp;<a href="https://wolf.financial/?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=will-the-us-ever-pay-off-its-debt" target="_blank" rel="noreferrer noopener">Here</a>.

Equities

Government

Opinion

Markets

ETFs

Will The US Ever Pay Off Its Debt? Here's Why We Think It Won't…

Maxim Group analyst Allen Klee initiates coverage on Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) with a Buy rating and announces Price Target of $5.

Initiation

OXBR

Maxim Group Initiates Coverage On Oxbridge Re Holdings with Buy Rating, Announces Price Target of $5

UBS Group AG&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>)&nbsp;shares are trading lower on Wednesday. The Swiss bank reported&nbsp;first-quarter 2025 sales of&nbsp;$12.56 billion. This marked a 1% year-over-year decline and <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">fell short of the $12.99 billion consensus estimate</a>.
Underlying revenues declined slightly&nbsp;Y/Y to&nbsp;$11.9 billion.&nbsp;Underlying revenues from the core businesses rose 6% Y/Y, while revenues in the much-reduced Noncore and Legacy division declined 72% Y/Y.
Underlying operating profit before tax reached&nbsp;$2.59 billion, down 1%&nbsp;Y/Y in the quarter.
Global Wealth&nbsp;Management's&nbsp;net new assets for the&nbsp;quarter were&nbsp;$32 billion, with revenues rising&nbsp;<a target="_blank" href="https://www.ubs.com/global/en/investor-relations/press-releases/overview-news-display-ndp/en-20250430-1q25-quarterly-result.html?caasID=CAAS-ActivityStream" rel="noreferrer noopener">5</a>%&nbsp;Y/Y to&nbsp;$6.25 billion.
The group posted a net profit attributable to shareholders of&nbsp;$1.69 billion&nbsp;for the quarter vs. $1.76 billion a year ago quarter. EPS&nbsp;of&nbsp;51 cents&nbsp;beat the consensus of&nbsp;41 cents.
The CET1 capital ratio, a measure of bank liquidity, was&nbsp;14.3%, compared to 14.8% in the year-ago quarter.
UBS CEO&nbsp;Sergio P. Ermotti stated, "The power and scale of our diversified global franchise, coupled with our continued focus on clients, drove strong business momentum in the quarter and net new inflows in our asset-gathering businesses."
"With increased uncertainty in markets and the macroeconomic outlook, we continue to focus on supporting clients, delivering on our financial targets, and acting as an engine of economic growth in the communities we serve."
Buyback: The bank completed share buybacks&nbsp;worth $0.5 billion and reserved $2.5 billion for planned share repurchases for the remainder of 2025.
Outlook: In the second quarter, UBS anticipates a low-single-digit percentage sequential decline in net interest income (NII) within Global Wealth Management and a similar decrease in Swiss franc terms <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">for Personal &amp; Corporate Banking's NII</a>.
Meanwhile, Personal &amp; Corporate Banking's NII is expected to increase sequentially by a mid-single-digit percentage in USD terms.
The bank noted that the continued market uncertainty could potentially delay the execution of their Global Banking pipeline.
Pull-to-par revenues are projected to reach $0.6 billion, which is anticipated to offset the expected $1.1 billion in integration-related expenses partly.
Investors can gain exposure to the stock via&nbsp;the Avantis International Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVDE#NYSE">AVDE</a>) and&nbsp;the Elevation Series Trust The Opal International Dividend Income ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IDVZ#BATS">IDVZ</a>).
Price Action:&nbsp;UBS shares are down&nbsp;1.57%&nbsp;at&nbsp;$30.03 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44762037" target="_blank" rel="noreferrer noopener">Morgan Stanley Q1 Credit Loss Provision Jumps To $135 Million On ‘Weakening Macroeconomic Forecast,' Equity Revenue Jumps 45%</a></li>
</ul>
Photo via Shutterstock

Earnings

Large Cap

Guidance

Eurozone

Movers

AVDE

Elevation Series Trust The Opal International Dividend Income ETF

IDVZ

Why Is UBS Stock Trading Lower On Wednesday?

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=LLY" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is up 14.35% over the past year, 14.79% YTD.
Let&#8217;s examine the charts for Eli Lilly stock and how it currently compares to Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/insights/news/25/04/45024735/1000-invested-in-this-stock-20-years-ago-would-be-worth-this-much-today">$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today</a>
<h2 class="wp-block-heading">LLY Stock Chart Strongly Bullish Ahead Of Q1 Earnings</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30125527/Screenshot-2025-04-30-at-10.24.51-PM.png" alt="" class="wp-image-895429" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30125527/Screenshot-2025-04-30-at-10.24.51-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30125527/Screenshot-2025-04-30-at-10.24.51-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Eli Lilly&#8217;s stock is flashing a strongly bullish technical setup, with its stock at $896.20, trading well above key moving averages across the board. Specifically, the company&#8217;s stock is comfortably positioned above its five-day, 20-day and 50-day exponential moving averages, signaling firm upward momentum and sustained buying interest.
The stock also trades above its eight-day simple moving average (SMA) of $859.74, its 20-day SMA of $798.34 and its 50-day SMA of $834.64 &#8211; all clear bullish signals indicating technical strength.
Adding further support, Eli Lilly remains above its 200-day SMA of $844.59, a long-term bullish indicator watched closely by institutional investors. The Moving Average Convergence Divergence (MACD) reading stands at 18.97, reinforcing the bullish momentum with a positive divergence.
Meanwhile, the Relative Strength Index (RSI) of 64.49 shows the stock is not yet overbought, suggesting room for continued upside. For investors, the technical setup suggests confidence in the trend, with potential for further gains if broader market sentiment cooperates.
<h2 class="wp-block-heading">Eli Lilly Analysts See 3% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/NFLX/analyst-ratings"> The consensus analyst rating</a> on Eli Lilly stock stands at a Buy currently with a price target of $945.70. The latest analyst ratings from HSBC, Cantor Fitzgerald and Guggenheim imply a 2.95% downside for Eli Lilly stock, with an average price target of $867.67.
Price Action: Eli Lilly stock was trading at $895.25 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45078101/eli-lilly-set-to-report-earnings-as-investors-eye-weight-loss-drug-momentum">Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Technicals

Previews

General

Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?

First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares are trading lower on Wednesday after the company reported worse-than-expected earnings for the first quarter and cut its <a href="https://in.benzinga.com/news/earnings/25/04/45085368/first-solar-falls-short-on-q1-earnings-cuts-fy-guidance-due-to-tariffs-shares-tumble">full-year outlook</a>.
What To Know: First Solar reported first-quarter earnings per share of $1.95, missing analyst estimates of $2.63. In addition, the solar company reported sales of $844.57 million, beating analyst estimates of $839.28 million, despite being down $700 million from the prior quarter.
Outlook: The company also cut its full-year 2025 guidance. First Solar previously projected earnings per share between $17 and $20, but said it now expects earnings per share of $12.50 to $17.50, below analyst estimates of $18.20.
The company also lowered its sales guidance from between $5.30 billion to $5.80 billion to a new range of between $4.50 billion to $5.50 billion, versus analyst estimates of $5.46 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;Despite the near-term challenges presented by the new tariff regime, we believe that the long-term&nbsp;outlook&nbsp;for solar demand, particularly in our core U.S. market, remains strong, and that First Solar remains well-positioned to serve this demand,&#8221; said Mark Widmar, CEO. 
&#8220;This belief is based on the unique profile of First Solar compared to its peers, as America&#8217;s largest, and most established solar module manufacturer, and the country&#8217;s only fully vertically integrated producer, our significant network of domestic supply chain vendors, and our proprietary CadTel-based semiconductor.&#8221;
Analyst Changes: Following the earnings report, Keybanc downgraded First Solar to Underweight and set a new price target of $100 and Oppenheimer analysts downgraded the stock to Perform. Multiple analyst firms also lowered <a href="https://www.benzinga.com/insights/analyst-ratings/25/04/45100958/a-glimpse-into-the-expert-outlook-on-first-solar-through-21-analysts">price targets</a>.
<ul>
<li>Wells Fargo analyst Michael Blum maintained an Overweight rating on First Solar and lowered the price target from $191 to $177.</li>
<li>RBC Capital analyst Christopher Dendrinos maintained an Outperform rating on First Solar and lowered the price target from $237 to $214.</li>
<li>BMO Capital analyst Ameet Thakkar maintained an Outperform rating on First Solar and lowered the price target from $200 to $187.</li>
<li>Goldman Sachs analyst Brian Lee maintained a Buy rating and lowered the price target from $235 to $204.</li>
</ul>
FSLR Price Action: At the time of publication, First Solar stock was down 9.74% at $123.88, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45108703/fresh-del-monte-stock-falls-as-q1-sales-earnings-miss-expectations">Fresh Del Monte Stock Falls As Q1 Sales, Earnings Miss Expectations</a></li>
</ul>
Image via Shutterstock.

Downgrades

FSLR

First Solar Stock Is Facing Heavy Selling Pressure Wednesday: What's Going On?

Ionis Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of a $1.12 loss</a>.
Revenue increased 10% in the first quarter of 2025 to $132 million, beating the consensus of $125.32 million, driven by <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45095541/ionis-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">higher commercial revenue</a>.
<ul>
<li>Tryngolza&nbsp;(olezarsen), the first-ever treatment for familial chylomicronemia syndrome as an adjunct to diet, generated net product sales of over&nbsp;$6 million&nbsp;in its first full quarter following approval in the&nbsp;U.S.&nbsp;on&nbsp;Dec. 19, 2024. A European approval decision is anticipated in the second half of 2025.</li>
<li>Wainua (eplontersen) (Wainzua in the EU) for polyneuropathy of hereditary transthyretin-mediated amyloidosis generated sales of $39 million, resulting in royalty revenue of $9 million in the first quarter of 2025.</li>
<li>Spinraza (nusinersen) for spinal muscular atrophy generated global sales of&nbsp;$424 million, resulting in royalty revenue of&nbsp;$48 million&nbsp;in the first quarter of 2025.
<ul>
<li>Higher dose nusinersen is under review for marketing approval in the U.S. (PDUFA date of Sept. 22, 2025) and the EU.</li>
</ul>
</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44672086/rna-drugmaker-ionis-pharmaceuticals-highlighted-for-deep-pipeline-and-cash-flow-analyst-initiates-with-bullish-tone" rel="noreferrer noopener">Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For &#8216;Pipeline Depth&#8217;</a>
"We are increasing our 2025 financial guidance, including raising revenue guidance by more than 20 percent due to our strong first quarter results and recent successful licensing transactions. We are also substantially improving our operating loss and cash guidance &#8230; Our strong financial position and commitment to drive operating leverage position Ionis to advance our strategic priorities and successfully navigate the dynamic macroeconomic environment," said&nbsp;Elizabeth L. Hougen, Ionis chief financial officer.
 "Moving forward, the three additional independent launches anticipated over the next couple of years position Ionis to deliver substantial and growing product revenue. This product revenue coupled with anticipated increasing royalty revenue from multiple partner launches and disciplined investment, position Ionis to achieve sustained positive cash flow,&#8221; Hougen added.
Guidance:&nbsp;Ionis Pharmaceuticals forecasts 2025 revenue of $725-$750 million <a href="https://www.benzinga.com/25/02/43818962/ionis-pharmaceuticals-says-2024-revenue-exceeds-guidance-on-sales-from-diverse-sources-forecasts-over-600-million-in-2025-sales" target="_blank" rel="noreferrer noopener">compared to prior guidance</a> of over $600 million and the consensus of $659.37 million.
The company expects a 2025 adjusted operating loss of less than $375 million compared to prior guidance of less than $495 million, with cash, cash equivalents, and short-term investments of ~$1.9 billion (vs. ~$1.7 billion expected earlier).
IONS Price Action: Ionis stock is up 2.01% at $30.41 at publication on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45106948/norwegian-cruise-line-tumbles-after-earnings-miss-still-confident-in-2025-guidance" target="_blank" rel="noreferrer noopener">Norwegian Cruise Line Tumbles After Earnings Miss, Still Confident In 2025 Guidance</a></li>
</ul>

IONS

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Lake Street analyst Jaeson Schmidt maintains Benchmark Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) with a Buy and lowers the price target from $52 to $46.

Lake Street Maintains Buy on Benchmark Electronics, Lowers Price Target to $46

Visa Unveils Visa Intelligent Commerce, Enabling AI to Discover and Purchase Products at the Visa Global Product Drop

Lake Street analyst Eric Martinuzzi maintains Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) with a Hold and raises the price target from $2.75 to $4.

EVLV

Lake Street Maintains Hold on Evolv Technologies, Raises Price Target to $4

Bank of the James Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTJ#NASDAQ">BOTJ</a>) reported quarterly earnings of $0.19 per share. This is a 60.42 percent decrease over earnings of $0.48 per share from the same period last year. The company reported $11.00 million in sales this quarter. This is a 7.26 percent increase over sales of $10.26 million the same period last year.

BOTJ

Bank of the James Finl Gr Q1 EPS $0.19 Down From $0.48 YoY, Sales $11.00M Up From $10.26M YoY

Acadian Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAMI#NYSE">AAMI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.
Analysts estimate that Acadian Asset Management will report an earnings per share (EPS) of $0.50. 
Investors in Acadian Asset Management are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.36, which was followed by a 0.08% increase in the share price the next day.
Here's a look at Acadian Asset Management's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.94</td>
<td>0.48</td>
<td>0.41</td>
<td>0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.30</td>
<td>0.59</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>4.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746036177_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Acadian Asset Management were trading at $26.69 as of April 29. Over the last 52-week period, shares are up 17.11%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Acadian Asset Management</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Acadian Asset Management.
With 3 analyst ratings, Acadian Asset Management has a consensus rating of Neutral. The average one-year price target is $25.33, indicating a potential 5.1% downside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Virtus Inv, P10 and WisdomTree, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Underperform trajectory for Virtus Inv, with an average 1-year price target of $183.14, suggesting a potential 586.17% upside.</li>
<li>Analysts currently favor an Outperform trajectory for P10, with an average 1-year price target of $14.0, suggesting a potential 47.55% downside.</li>
<li>Analysts currently favor an Sell trajectory for WisdomTree, with an average 1-year price target of $8.5, suggesting a potential 68.15% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Virtus Inv, P10 and WisdomTree are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acadian Asset Management</td>
<td>Neutral</td>
<td>27.90%</td>
<td>$91.70M</td>
<td>4047.62%</td>
</tr>
<tr>
<td>Virtus Inv</td>
<td>Underperform</td>
<td>-6.69%</td>
<td>$126.21M</td>
<td>3.20%</td>
</tr>
<tr>
<td>P10</td>
<td>Outperform</td>
<td>34.80%</td>
<td>$45.59M</td>
<td>1.51%</td>
</tr>
<tr>
<td>WisdomTree</td>
<td>Sell</td>
<td>21.85%</td>
<td>$57.81M</td>
<td>6.76%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Acadian Asset Management ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>Discovering Acadian Asset Management: A Closer Look</h3>
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
<h3>A Deep Dive into Acadian Asset Management's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Acadian Asset Management displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 27.9%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Acadian Asset Management's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 25.33%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Acadian Asset Management's ROE stands out, surpassing industry averages. With an impressive ROE of 4047.62%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Acadian Asset Management's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.75%, the company showcases efficient use of assets and strong financial health.
Debt Management: Acadian Asset Management's debt-to-equity ratio is notably higher than the industry average. With a ratio of 17.08, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/AAMI/earnings">To track all earnings releases for Acadian Asset Management visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAMI

A Glimpse of Acadian Asset Management's Earnings Potential

ACCO Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACCO#NYSE">ACCO</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate ACCO Brands to report an earnings per share (EPS) of $-0.04.
The market awaits ACCO Brands's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 17.39% drop in the share price the following trading session.
Here's a look at ACCO Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.41</td>
<td>0.23</td>
<td>0.31</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.39</td>
<td>0.23</td>
<td>0.37</td>
<td>0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-17.0%</td>
<td>7.000000000000001%</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746036168_0.png" alt="eps graph" />
<h3>Performance of ACCO Brands Shares</h3>
Shares of ACCO Brands were trading at $3.92 as of April 29. Over the last 52-week period, shares are down 21.85%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Opinions on ACCO Brands</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on ACCO Brands.
Analysts have given ACCO Brands a total of 1 ratings, with the consensus rating being Outperform. The average one-year price target is $7.0, indicating a potential 78.57% upside.
<h3>Comparing Ratings with Competitors</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Interface and MSA Safety, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Interface, with an average 1-year price target of $30.0, suggesting a potential 665.31% upside.</li>
<li>Analysts currently favor an Neutral trajectory for MSA Safety, with an average 1-year price target of $168.0, suggesting a potential 4185.71% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Interface and MSA Safety, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCO Brands</td>
<td>Outperform</td>
<td>-8.29%</td>
<td>$155.50M</td>
<td>3.37%</td>
</tr>
<tr>
<td>Interface</td>
<td>Outperform</td>
<td>3.04%</td>
<td>$122.31M</td>
<td>4.38%</td>
</tr>
<tr>
<td>MSA Safety</td>
<td>Neutral</td>
<td>0.88%</td>
<td>$234.43M</td>
<td>7.88%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ACCO Brands ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.
<h3>Discovering ACCO Brands: A Closer Look</h3>
ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.
<h3>Understanding the Numbers: ACCO Brands's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: ACCO Brands's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -8.29%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: ACCO Brands's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 4.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): ACCO Brands's ROE excels beyond industry benchmarks, reaching 3.37%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ACCO Brands's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.9%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.52, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/ACCO/earnings">To track all earnings releases for ACCO Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCO

What's Next: ACCO Brands's Earnings Preview

Quaker Houghton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.
Analysts estimate that Quaker Houghton will report an earnings per share (EPS) of $1.61. 
The announcement from Quaker Houghton is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.19, which was followed by a 2.61% increase in the share price the next day.
Here's a look at Quaker Houghton's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.52</td>
<td>2.11</td>
<td>2.21</td>
<td>1.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.33</td>
<td>1.89</td>
<td>2.13</td>
<td>2.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>6.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746036159_0.png" alt="eps graph" />
<h3>Quaker Houghton Share Price Analysis</h3>
Shares of Quaker Houghton were trading at $105.98 as of April 29. Over the last 52-week period, shares are down 45.42%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Quaker Houghton</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Quaker Houghton.
The consensus rating for Quaker Houghton is Neutral, based on 4 analyst ratings. With an average one-year price target of $147.25, there's a potential 38.94% upside.
<h3>Comparing Ratings with Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Minerals Technologies, Perimeter Solutions and Innospec, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Minerals Technologies, with an average 1-year price target of $89.0, suggesting a potential 16.02% downside.</li>
<li>Analysts currently favor an Buy trajectory for Perimeter Solutions, with an average 1-year price target of $14.0, suggesting a potential 86.79% downside.</li>
<li>Analysts currently favor an Buy trajectory for Innospec, with an average 1-year price target of $155.0, suggesting a potential 46.25% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary presents essential metrics for Minerals Technologies, Perimeter Solutions and Innospec, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quaker Houghton</td>
<td>Neutral</td>
<td>-4.93%</td>
<td>$156.20M</td>
<td>1.01%</td>
</tr>
<tr>
<td>Minerals Technologies</td>
<td>Buy</td>
<td>-7.99%</td>
<td>$119.60M</td>
<td>-8.61%</td>
</tr>
<tr>
<td>Perimeter Solutions</td>
<td>Buy</td>
<td>45.04%</td>
<td>$41.90M</td>
<td>13.36%</td>
</tr>
<tr>
<td>Innospec</td>
<td>Buy</td>
<td>-5.64%</td>
<td>$136.20M</td>
<td>-5.74%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Quaker Houghton ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Quaker Houghton is at the bottom compared to its peers.
<h3>Unveiling the Story Behind Quaker Houghton</h3>
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
<h3>Understanding the Numbers: Quaker Houghton's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Quaker Houghton faced challenges, resulting in a decline of approximately -4.93% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Quaker Houghton's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 3.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Quaker Houghton's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.01%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Quaker Houghton's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.53% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.55, Quaker Houghton adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/KWR/earnings">To track all earnings releases for Quaker Houghton visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Quaker Houghton's Upcoming Earnings Report

Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Velocity Financial will report an earnings per share (EPS) of $0.56.
The announcement from Velocity Financial is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.12, leading to a 8.47% increase in the share price on the subsequent day.
Here's a look at Velocity Financial's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.48</td>
<td>0.48</td>
<td>0.41</td>
<td>0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.60</td>
<td>0.47</td>
<td>0.45</td>
<td>0.51</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>2.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746036151_0.png" alt="eps graph" />
<h3>Performance of Velocity Financial Shares</h3>
Shares of Velocity Financial were trading at $17.87 as of April 29. Over the last 52-week period, shares are up 2.94%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/VEL/earnings">To track all earnings releases for Velocity Financial visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Velocity Financial's Quarterly Earnings

Scorpio Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STNG#NYSE">STNG</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Scorpio Tankers will report an earnings per share (EPS) of $2.65.
The market awaits Scorpio Tankers's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.02, leading to a 6.69% drop in the share price on the subsequent day.
Here's a look at Scorpio Tankers's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.65</td>
<td>2.10</td>
<td>3.59</td>
<td>3.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.63</td>
<td>1.75</td>
<td>3.60</td>
<td>3.97</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>-2.0%</td>
<td>-0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746036142_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Scorpio Tankers were trading at $37.8 as of April 29. Over the last 52-week period, shares are down 47.38%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about Scorpio Tankers</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Scorpio Tankers.
The consensus rating for Scorpio Tankers is Buy, derived from 3 analyst ratings. An average one-year price target of $61.33 implies a potential 62.25% upside.
<h3>Peer Ratings Comparison</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Global Partners, DHT Holdings and Frontline, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Global Partners, with an average 1-year price target of $56.0, suggesting a potential 48.15% upside.</li>
<li>Analysts currently favor an Buy trajectory for DHT Holdings, with an average 1-year price target of $13.5, suggesting a potential 64.29% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Frontline, with an average 1-year price target of $20.0, suggesting a potential 47.09% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
In the peer analysis summary, key metrics for Global Partners, DHT Holdings and Frontline are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scorpio Tankers</td>
<td>Buy</td>
<td>-39.35%</td>
<td>$66.11M</td>
<td>2.40%</td>
</tr>
<tr>
<td>Global Partners</td>
<td>Neutral</td>
<td>-5.05%</td>
<td>$268.83M</td>
<td>2.47%</td>
</tr>
<tr>
<td>DHT Holdings</td>
<td>Buy</td>
<td>-8.36%</td>
<td>$38.56M</td>
<td>5.31%</td>
</tr>
<tr>
<td>Frontline</td>
<td>Outperform</td>
<td>2.56%</td>
<td>$113.58M</td>
<td>2.85%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Scorpio Tankers ranks at the bottom for Revenue Growth, with the lowest percentage among peers. It also has the lowest Gross Profit among the group. However, it has the highest Return on Equity, indicating strong performance in this aspect compared to its peers.
<h3>Discovering Scorpio Tankers: A Closer Look</h3>
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
<h3>Financial Milestones: Scorpio Tankers's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Scorpio Tankers's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -39.35%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Scorpio Tankers's net margin excels beyond industry benchmarks, reaching 33.61%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.4%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Scorpio Tankers's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.78% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Scorpio Tankers's debt-to-equity ratio is below the industry average. With a ratio of 0.3, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/STNG/earnings">To track all earnings releases for Scorpio Tankers visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STNG

Scorpio Tankers's Earnings: A Preview

Savers Value Village (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-01. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Savers Value Village to report an earnings per share (EPS) of $0.07.
The announcement from Savers Value Village is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 19.45% drop in the share price on the subsequent day.
Here's a look at Savers Value Village's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.13</td>
<td>0.16</td>
<td>0.20</td>
<td>0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>0.15</td>
<td>0.14</td>
<td>0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-19.0%</td>
<td>-8.0%</td>
<td>-9.0%</td>
<td>-20.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746036127_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Savers Value Village were trading at $9.3 as of April 29. Over the last 52-week period, shares are down 41.58%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on Savers Value Village</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Savers Value Village.
The consensus rating for Savers Value Village is Neutral, based on 3 analyst ratings. With an average one-year price target of $10.67, there's a potential 14.73% upside.
<h3>Peer Ratings Overview</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of and Savers Value Village, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for and Savers Value Village, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Savers Value Village</td>
<td>Neutral</td>
<td>5.02%</td>
<td>$223.81M</td>
<td>-0.44%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Savers Value Village ranks in the middle among peers for consensus rating. It is at the bottom for revenue growth, indicating slower growth compared to peers. The company's gross profit is also at the bottom, suggesting lower profitability. Additionally, its return on equity is negative, reflecting poor performance in utilizing shareholder equity.
<h3>Get to Know Savers Value Village Better</h3>
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, merchandise, and sells these items in its stores.
<h3>Savers Value Village: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Savers Value Village displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 5.02%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Savers Value Village's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Savers Value Village's ROE excels beyond industry benchmarks, reaching -0.44%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Savers Value Village's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.1%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Savers Value Village's debt-to-equity ratio stands notably higher than the industry average, reaching 3.09. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/SVV/earnings">To track all earnings releases for Savers Value Village visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Savers Value Village's Upcoming Earnings

Beazer Homes USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BZH#NYSE">BZH</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Beazer Homes USA will report an earnings per share (EPS) of $0.29.
Investors in Beazer Homes USA are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.21 in the last quarter, leading to a 20.0% drop in the share price on the following day.
Here's a look at Beazer Homes USA's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.31</td>
<td>1.35</td>
<td>0.83</td>
<td>0.91</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>1.69</td>
<td>0.88</td>
<td>1.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-20.0%</td>
<td>8.0%</td>
<td>-13.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746036100_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Beazer Homes USA were trading at $19.35 as of April 29. Over the last 52-week period, shares are down 28.23%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BZH/earnings">To track all earnings releases for Beazer Homes USA visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Beazer Homes USA

Press Releases

NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

Comments

NKGen Biotech

Noticias

Últimas noticias sobre NKGen Biotech (OTC:NKGN) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL